Abstract OBJECTIVES: Surgical treatments for metachronous second primary lung cancer (MSPLC) may be increasing. It was thought that surgery for MSPLC is associated with high mortality and morbidity. However, recent diffusion of minimally invasive surgical procedures may improve the safety of surgery for MSPLC. The aim of this study was to clarify the safety and prognosis of surgery for MSPLC compared with that for primary lung cancer (PLC).
INTRODUCTION
The incidence of metachronous second primary lung cancer (MSPLC) after curative resection for the primary lung cancer (PLC) may be increasing due to postoperative follow-up surveillance and improved overall survival after curative resection for PLC [1] . The incidence of MSPLC in patients with resected non-small-cell lung cancer (NSCLC) reportedly ranges from 0.8% to 14.5% per patient per year [1] [2] [3] , and a majority of MSPLCs were detected during postoperative radiological surveillance after resection for PLC [4] . Recent advances in radiological surveillance, such as high-resolution computed tomography (CT) and 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET), apparently contribute in detecting a larger number of small-sized or early-stage NSCLCs. Therefore, MSPLC can often be treated with surgical resection. Many studies have suggested that surgery for MSPLC may be associated with improved overall survival [2, 3, [5] [6] [7] [8] [9] [10] [11] [12] . However, pulmonary resection for MSPLC is essentially performed for patients who received previous ipsilateral or contralateral thoracotomy or video-assisted thoracoscopic surgery (VATS). Patient selection and the extent of pulmonary resection are important, because these patients tend to have limited cardiopulmonary functions [12] . According to previous literature, operative mortality and morbidity of patients undergoing pulmonary resection for MSPLC were relatively higher than that of resection for PLC [5, 7, 9, 11, 12] , which may make surgeons hesitant to proceed with surgical treatments for MSPLC.
Recently, pulmonary resection for NSCLC has changed remarkably with the widespread use of minimally invasive surgical techniques, such as VATS and sublobar resection for early-stage NSCLC [13] . When these minimally invasive techniques are applied to the resection for PLC and/or MSPLC, cardiopulmonary function may be well preserved and operative mortality and morbidity rates may decrease. However, to our knowledge, no reports have focused on postoperative mortality and complications for reoperative pulmonary resection in the current era, when minimally invasive approachs and resection are widely utilized. The purpose of this study was to compare long-term survival and postoperative complications among patients with PLC and those with MSPLC.
PATIENTS AND METHODS

Patients
A Retrospective chart review was performed on our prospectively maintained database of patients undergoing pulmonary resection for NSCLC. A total of 1340 patients underwent pulmonary resection for NSCLC with curative intent between January 2006 and December 2013 at our institution. The number of Patients who underwent first-time lung resection and second subsequent lung resection totalled 1264 and 76, respectively. Among the 76 patients, 23 patients were excluded from the study because they underwent pulmonary resection for synchronous second PLC, resection for recurrent lung cancer or resection for PLC after pulmonary resection for benign lung disease. Twenty-seven patients who underwent first-time lung resection for PLC were excluded from the PLC group because they received resection for MSPLC later and were classified in the MSPLC group. Finally, 53 patients who underwent pulmonary resection for MSPLC and 1237 patients who underwent resection for PLC were included in this study (Fig. 1) .
In this study, the definition of MSPLC was based on the criteria reported by Martini and Melamed [14] . In brief, a different histological type, or in the case of the same histological type, the free interval between cancers was at least 2 years, the original carcinoma was in situ and the second cancer was in a different lobe or lung. In addition, molecular biological analysis of tumours (epidermal growth factor receptor) or immunostaining (P53, TTF1, etc.) was performed when indicated to rule out metastasis.
Each case was discussed by a multidisciplinary tumour board, and histological comparisons of the initial and the subsequent cancer were performed by an experienced pathologist.
Perioperative management and follow-up surveillance
All patients underwent preoperative cardiopulmonary evaluation, electrocardiography, chest roentgenography, pulmonary function test and echocardiography and/or coronary angiography if needed as well as chest CT, FDG-PET and brain magnetic resonance imaging for preoperative staging. We selected patients undergoing surgery for MSPLC in terms of resectability and cardiopulmonary reserve. Specifically, complete resection was determined based on the radiological findings. Pulmonary reserve was determined based on the guideline of risk evaluation for lung cancer surgery (the Japanese Association of Chest Surgery). Criteria for surgical resection or the extent of resection were predicted postoperative % forced expiratory volume in 1 s (FEV1.0) > _40 and predicted postoperative FEV1.0 > _800 ml [15] . Even in candidates for lobectomies from cardiopulmonary standpoints, sublobar resection is preferred in some cases at the discretion of the surgeon.
Among them, a partial resection was performed in cases in which the tumour location was in the peripheral side or in cases in which the performance status or cardiopulmonary function were too poor to tolerate a sublobar resection.
After surgery, the patients were observed in a monitored setting for 1-2 days. Chest X-ray was repeated every day until chest drain removal, and a blood test was taken as often as required. Physical examination was performed daily until hospital discharge. Application of postoperative chemotherapy was performed preferentially. Tegafur/uracil was administered as postoperative chemotherapy in patients with pathological Stage IB. Intravenous postoperative chemotherapy with platinumbased regimens was administered in patients with Stage II or III lung cancer with no renal or hepatic dysfunction. Postoperative chemoradiation therapy for patients with N2 disease was given. If the resection margins were positive in patients with N2 disease, concurrent chemoradiation was recommended for an R2 resection, whereas either concurrent or sequential chemoradiation was recommended for an R1 resection [16] .
Postoperative follow-up was continued for at least 5 years with medical check-ups and chest X-rays taken at least twice per year and a whole-body CT scan annually. Patients with Stage II or III NSCLC also received a brain magnetic resonance imaging annually. We followed up patients for at least 5 years after surgery.
Data collection
In this study, postoperative complications included new-onset atrial fibrillation, prolonged air leak, atelectasis, surgical site infection, pneumonia, respiratory failure, chronic chest wall pain and deliria. Postoperative complications were defined as the occurrence of any adverse effects within 30 days after surgery, except for respiratory failure and chest wall pain. Respiratory failure was defined as residual dyspnoea on effort or receiving home oxygen therapy even after 60 days post-surgery, and chronic chest wall pain was defined as receiving analgesic medications even after 60 days post-surgery. The incidence of any of those complications was also calculated.
The severity of postoperative complications was graded according to the Clavien-Dindo (C-D) classification that is specific to postoperative complications [17] . According to the C-D classification, 'Grade II or more' complications are defined as postoperative complication in this study. Grade II is defined as a case requiring pharmacological treatment.
Statistical analyses
We matched patients on a propensity score basis to evaluate the postoperative complications of a resection for MSPLC compared with a resection for PLC. The propensity score for MSPLC was constructed using a binary logistic regression that included patient age, gender, clinical and pathological stage, clinical tumour size, preoperative PS, preoperative FEV1, preoperative forced vital capacity, extent of resection, surgical approach, mediastinal lymph node dissection, pathological histology and tumour differentiation grade. Nearest neighbour matching with a caliper difference of 0.2 was used to match 50 patients with MSPLC (matched MSPLC group) and 50 patients with PLC (matched PLC group). Categorical variables were compared with the v 2 test. Continuous variables were compared with the Mann-Whitney U-test. Overall survival was calculated from the day of surgery to death or last follow-up, estimated using the Kaplan-Meier method and was compared with a log-rank test. All statistical tests were 2 sided, and a P-value of <0.05 was considered statistically significant. All statistical analyses were performed using the JMP software version 12. The study protocol was approved by the institutional review board (reference number: E 2471).
RESULTS
Patient demographics
The patient characteristics are listed in Table 1 . There were significant differences between the PLC group and the MSPLC group regarding tumour size on CT, clinical stage, preoperative FEV1.0, extent of resection and mediastinal lymph node dissection. Detailed characteristics of the MSPLC group are summarized in Table 2 . None of the patients underwent a completion pneumonectomy in this study. Among them, 13 (24.5%) patients had ipsilateral MSPLC and 40 (75.5%) patients had contralateral MSPLC. Forty-eight (90.6%) patients underwent lobectomy as a prior surgery. Twenty-three (43.4%) patients underwent pulmonary resection via VATS approach as a prior surgery.
Postoperative complications
We performed comparison of postoperative complications between all patients of the PLC (n = 1237) and all patients of the MSPLC (n = 53) groups in univariable analysis. There was no significant difference between the two groups (Supplementary Material, File S1).
Patient characteristics after propensity score matching are listed in Table 3 . Fifty MSPLC patients and 50 PLC patients were matched blinded to outcomes (1:1 ratio, caliper distance 0.2). Three cases with MSPLC were dropped from propensity score matching. These patients underwent wedge resection with open procedure.
In the matched MSPLC group, 1 or more postoperative complications of Grade II or more severity occurred in 11 (22.0%) patients, prolonged air leak in 6 (12.0%) patients, atrial fibrillation in 1 (2.0%) patient, postoperative pneumonia in 1 (2.0%) patient, respiratory failure in 2 (4.0%) patients, surgical site infection in 1 (2.0%) patient, atelectasis in 1 (2.0%) patient and delirium in 1 (2.0%) patient.
Among them, postoperative complications of Grade IIIa occurred in 4 (8.0%) patients, prolonged air leak in 2 (4.0%) patients, postoperative pneumonia in 1 (2.0%) patient and surgical site infection in 1 (2.0%) patient. Grade IIIb or more complications did not occur in the MSPLC group. A univariable analysis showed that overall and each postoperative complication rates in matched MSPLC group were not significantly different from those in the matched PLC group (Table 4) .
Although we compared the postoperative complications between ipsilateral procedure (n = 13) and contralateral procedure (n = 40) among MSPLC patients, no significant difference was observed (Supplementary Material, File S2).
Long-term survival
The median follow-up time calculated with the reverse Kaplan-Meier method was 46.4 months in the matched MSPLC group and 47.9 months in the matched PLC group. The 5-year overall survival rates were 68.7% (95% confidence interval 5.8-99.7%) and 83.0% (95% confidence interval 67.8-99.9%) in the PLC and the MSPLC patient groups, respectively. There was no significant difference between those with PLC and those with MSPLC in overall survival (P = 0.2018, by log-rank test) (Fig. 2) .
DISCUSSION
The purpose of this study was to compare the safety and prognosis of surgery for PLC with MSPLC. We performed a comparison of all PLC cases with all MSPLC cases before propensity score matching. There was no significant difference between them; however, there was some bias in the background of patients between them. There was also a possibility that sublobar resection was selected in PLC because tumour size was small and the oncological characteristics were relatively mild. On the other hand, sublobar resection was selected in MSPLC because cardiopulmonary function was too poor for lobectomy. To eliminate these factors, we included 'pathological histology' and 'tumour differentiation grade' in the propensity score matching. Although there remained some bias after propensity score matching, the limitation was improved when we compared the short-term postoperative complications with the long-term survival outcomes.
Three cases with MSPLC were dropped from the propensity score match. These patients underwent wedge resection with an open procedure. They were dropped from the propensity score match primarily because there were few cases of open surgery for wedge resection in the PLC group. Also, patients with PLC who underwent open surgery for wedge resection had a relatively better pulmonary reserve than patients with MSPLC. Operative mortality following a resection for MSPLC reported in previous studies was relatively higher (1.4-12.8%) [5, 7, 9, 11, 12] than that of a resection for PLC (0.7-3.1%) [13, [18] [19] [20] . Hamaji et al. [10] designed the meta-analysis of a resection for MSPLC and demonstrated a pooled operative mortality rate of 7% and a pooled operative morbidity rate of 32%. However, studies included in that meta-analysis involved patients undergoing completion pneumonectomy via an open thoracotomy, which appeared to be associated with a higher morbidity. In some studies, a completion pneumonectomy comprised more than 20% of total cases [7, 9, 11] . On the contrary, in our study, a majority of patients with MSPLC underwent sublobar resection. The proportion of sublobar resections in this study appear to be higher than those in previous studies [3, 5, 7, 9, 11, 12] . We theorized that avoiding completion pneumonectomy might contribute to eliminating operative mortality and a low morbidity rate in patients with MSPLC.
Although the definition of postoperative morbidity varies, operative morbidity following a resection for MSPLC reported in previous studies ranges from 19 .0% to 36.2% [3, 5, [8] [9] [10] [11] [12] 19] . Hamaji et al. [10] also demonstrated a pooled operative morbidity of 32% in their meta-analysis of resection for MSPLC. Our postoperative complication rate of 22% appears to be more favourable than the pooled rate of postoperative morbidity, but a statistical comparison is impossible, given the varying definitions of morbidity. The incidence of postoperative atrial fibrillation was low in the MSPLC group (2.0%). We believe this is attributed to a small sample size and the fact that 'Grade II or more in C-D classification' complications were defined as a postoperative complication in this study. In the MSPLC group, 46 (92.0%) patients had pathological Stage I lung cancer in our study. Forty-one (82.0%) patients underwent sublobar resection (segmentectomy or wedge resection), and VATS approach was used in 36 (72.0%) patients. These high rates of minimally invasive surgery (VATS or sublobar resection) for second PLC have not been described in previous studies. The proportion of sublobar resection ranged from 29.9% to 77% [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 19] , and VATS was only employed in 21.7-27.3% of resections for MSPLC [3, 5] . Furthermore, there were many reports lacking information on surgical approaches [6-9, 11, 12] . We speculate that the high rate of VATS and sublobar resection in the MSPLC group may be associated with an acceptable rate of postoperative complications in our study. Although there was no significant difference, a longer operative time was observed in the MSPLC group, which resulted in more bleeding than the PLC group. One MSPLC case had high bleeding (2330 ml) and a prolonged operative time (568 min). This was an ipsilateral open thoracotomy case, for which a right upper lobectomy was performed, during which adhesion due to prior surgery (right lower lobectomy) was detected. We compared postoperative complication rates of ipsilateral and contralateral procedures but no significant difference was observed. Of note, our data did not achieve sufficient statistical power due to a small sample size. The MSPLC group had a higher rate of air leakage (12.0%) than the PLC group (6.0%). We concluded that this was of no concern in ipsilateral versus contralateral MSPLC because there were no ipsilateral cases among MSPLC patients with air leakage in this study. Among all cases of MSPLCs, the median interval from resection for PLC to resection for MSPLC was 42.0 months in our study; previous other studies demonstrated that the mean time interval was also within 5 years [3, 5, 7, 8] . In addition, 41 (79.2%) patients with MSPLCs were detected by radiological surveillance such as high-resolution CT or FDG-PET during the follow-up within 5 years of a resection for PLC. In the remaining 12 (22.6%) patients, MSPLC was detected after >5 years of surveillance, which suggests that postoperative surveillance of PLC for more than 5 years may have a role in detecting MSPLC. Almost all patients were followed up regularly for 5 years or more, and we could detect early-stage MSPLC with radiological surveillance such as high-resolution CT and FDG-PET. There was only 1 patient who was found to have MSPLC 10 years after a resection for PLC, and the general physicians caring for patients in the postoperative period may have to keep the possibility of MSPLC in mind while examining patients with a history of PLC. Lou et al. [4] demonstrated that almost all MSPLCs were detected by posttherapeutic surveillance CT, which reinforces our findings.
The 5-year overall survival rate of MSPLC was 68.7% in this study, which was more favourable than those from previous studies [3, [5] [6] [7] [8] [9] [10] [11] [12] . In our study, 46 (92.0%) patients in the MSPLC group had pathological Stage I lung cancer, which ranged from 64.7% to 96% in previous studies [3, 5, 12] , and only 1 study demonstrated a higher proportion of pathological Stage I than that of our study [8] . Lee et al. [4] demonstrated a 5-year overall survival rate of a resection for MSPLC of 65.0% (that was approximately equal to that in our study) and found 97% of patients to have pathological Stage I lung cancer. The high rate of resection at an early stage may reasonably be associated with a good survival rate.
Although no statistically significant difference was observed in overall survival between the groups with the log-rank test, a 68% vs a 83% 5-year-overall survival is a relatively large difference. We attribute the lack of statistical significance to the lack of statistical power.
In recent years, other (non-operative) treatment options are available, such as stereotactic body radiotherapy [21] [22] [23] [24] [25] , for patients who are considered to be at high risk for a lobectomy or marginally operable. Taioli et al. [24] suggested that patients undergoing a surgical resection are associated with a more favourable survival than patients undergoing radiotherapy for MSPLC. We should note that it is very difficult to adjust for confounding factors when comparing the 2 treatment modalities. Among the 1237 patients with PLC, 21 (1.7%) patients underwent stereotactic body radiotherapy for MSPLC after resection for PLC. We are currently planning to conduct this comparison in a separate study.
Limitations
There were several limitations inherent in this study. First, the study design was retrospective. Second, the sample size was relatively small and limited. Due to the small sample size, the study power is not sufficient. In this study, the study power was 27.2%, and 81 events were needed to gain 80% study power. [25] Twenty-one events were detected in this study. Staging and operative indication may not be consistent during the study period, which would be associated with selection bias.
Despite the above limitations, we believe our study will be an important one in comparing PLC and MSPLC, adjusting for measurable confounding factors. To obtain a larger sample size and identify significant prognostic factors for MSPLC, a multiinstitutional study of either a retrospective or a prospective design may validate our results.
CONCLUSION
Pulmonary resection for MSPLC was safely performed with acceptable postoperative morbidity and long-term overall survival.
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